However, to date, no large-scale clinical studies have evaluated the use of mTOR inhibitors for PEComa, although preliminary data are promising and suggest the possibility of complete response [12, 13]. Here, MTOR is linked to neoplasm with perivascular epithelioid cell differentiation.